Table I.
Initial Estimate of the CYP2C19 CR for Various Substrate Drugs
| Drug | CR | Reference |
|---|---|---|
| Amitriptyline | 0.28 | (32) |
| Citalopram | 0.54 | (33) |
| Cilostazol | 0.30 | (34) |
| Clomipramine | 0.43 | (35) |
| Clopidogrel | 0.66 | (36) |
| Diazepam | 0.84 | (37) |
| Escitalopram | 0.46 | (38) |
| Fluoxetine | 0.66 | (39) |
| Gliclazide | 0.81 | (40) |
| Lansoprazole | 0.74 | (41) |
| Lansoprazole R | 0.75 | (17) |
| Lansoprazole S | 0.87 | (17) |
| Mephobarbital R | 0.99 | (42) |
| Moclobemide | 0.72 | (43) |
| Nelfinavir | 0.47 | (44) |
| Nelfinavir active moietya | 0.25 | (44) |
| Omeprazole | 0.85 | (45) |
| Pantoprazole | 0.80 | (21) |
| Praziquantel | 0.17 | (46) |
| Proguanil | 0.93 | (47) |
| Rabeprazole | 0.74 | (41) |
| Sertraline | 0.69 | (22) |
| Sibutramine | 0.71 | (48) |
| Trimipramine | 0.48 | (49) |
| Voriconazole | 0.67 | (50) |
CR contribution ratio
aThe active moiety of nelfinavir is nelfinavir + M8 active metabolite (nelfinavir hydroxy-t-butylamide)